Yiling Pharmaceutical: The clinical trial application for the innovative chemical drug LB220-D08 sustained-release tablets has been accepted.

Yiling Pharmaceutical has announced that the company recently received the "Acceptance Notice" issued by the National Medical Products Administration. The clinical trial application for the innovative chemical drug LB220-D08 sustained-release tablets has been accepted, with acceptance numbers CXHL2600983 and CXHL2600984, and the acceptance date of August 12, 2026. This drug is a Class 1 new chemical entity independently developed by the company that acts as a complement inhibitor targeting Factor B, indicated for atypical hemolytic uremic syndrome.